On January 31, A-share listed Assure Tech (688075) released a full-year earnings forecast, in which the company expects its January-December 2022 results to rise sharply, with net profit attributable to shareholders of the listed company amounting to CNY 2.895 billion to CNY 3.378 billion, a net profit increase of 292.06% to 357.40% year-on-year.

The company makes the above forecast based on the following reasons: In FY2022, due to the impact of the global Covid-19 epidemic, the quality of the company's high-quality Covid-19 test products have been recognized by the market and customers, and the sales scale continues to expand, while non-Covid-19 test products also maintain steady growth.

The industry to which the company belongs is medical devices.

Assure Tech (Hangzhou) Co., Ltd. specializes in the R&D, production and sales of POCT reagents and instruments, and has a biological raw material technology platform for independent R&D and production of antigen and antibody, as well as a mature immunochromatographic and dry biochemical diagnostic technology platform, which has developed into a POCT reagent covering eight fields: drug detection, infectious disease detection, chronic disease detection, pregnancy detection, tumor detection, myocardial detection, biochemical detection and allergen detection. Our products are exported to many countries such as USA, Germany, UK, Canada, Russia, Mexico, Thailand, Indonesia and Poland, etc. We have become one of the few Chinese in vitro diagnostic product suppliers that can compete with multinational in vitro diagnostic industry giants in the international market of POCT.